PTC Buys a Fabry Disease Gene Therapy From Bankrupt Sangamo for Up to $211M

PTC Therapeutics is buying a gene therapy for Fabry disease from Sangamo Therapeutics in a deal worth up to $211 million — acquiring a late-stage asset after its onetime pioneer fell into bankruptcy.

Under the agreement dated August 13, 2026, PTC pays $111 million up front, plus $80 million tied to accelerated FDA approval and $20 million for full approval.

What Fabry disease does

Fabry is an inherited disorder in which a faulty GLA gene means a missing enzyme, so a fatty substance accumulates progressively in cells throughout the body.

The consequences build over decades. Damage to the kidneys can progress to failure requiring dialysis or transplant; damage to the heart causes thickening of the muscle and arrhythmias; and patients experience burning pain in the hands and feet, reduced sweating and gastrointestinal problems from early in life.

It is X-linked, so men are typically affected more severely, though women carrying the variant frequently develop significant disease as well.

Why a one-time therapy is attractive here

The Fabry treatment market is already worth more than $2 billion, and current care rests on enzyme replacement therapy — infusing the missing enzyme, typically every two weeks, indefinitely.

That works and has real limitations. Infusions consume hours every fortnight for life. The enzyme distributes unevenly, reaching some affected tissues poorly. And a proportion of patients develop antibodies against the infused enzyme, reducing its effectiveness.

A one-time infusion delivering a working copy of the GLA gene — ST-920 (isaralgagene civaparvovec) — would have the patient’s own cells produce the enzyme continuously, addressing both the burden and the distribution problem.

How Sangamo ended up selling

Sangamo was once a genetic-medicine trailblazer, undone by a series of setbacks and ill-fated partnerships, and filed for Chapter 11 bankruptcy. PTC won the asset at auction.

The company was among the earliest working on genome editing, pioneering zinc-finger nucleases well before CRISPR existed. That early position did not convert into approved products, and several large pharmaceutical partnerships were terminated as programmes underdelivered.

Being first in a field is not the same as winning it, and a company that establishes a technology can be overtaken by tools that arrive later and prove easier to use.

Eli Lilly separately won other Sangamo assets including its zinc-finger technology for $50 million — a platform two decades in development, sold for a fraction of what was invested in it.

Why the price is low for the stage

$111 million upfront for an asset with a rolling FDA submission underway is a modest sum. A comparable late-stage rare-disease programme sold outside bankruptcy would command considerably more.

The discount reflects the seller’s position rather than the asset’s quality. A bankrupt company sells on a court-supervised timetable to whoever bids, and the price reflects the pool of bidders willing to move quickly on those terms rather than what a competitive process would produce.

The milestone structure — $80 million on accelerated approval, $20 million on full — also shifts risk toward the buyer’s success rather than the seller’s valuation.

Why PTC is a sensible acquirer

PTC specialises in rare disease and already has commercial infrastructure for exactly this kind of product — small patient populations, specialist prescribers, complex reimbursement.

That matters because rare-disease commercialisation is a distinctive capability. Identifying scattered patients, working with a handful of expert centres and negotiating payer coverage for a high-priced therapy is a different exercise from selling a primary care drug, and a company that already does it can absorb another product cheaply.

What comes next

PTC plans to complete the rolling submission in the fourth quarter of 2026, with a potential launch in 2027. An analyst called it “a prudent deal with low risk and strong upside.”

What bankruptcy sales say about the sector

Sangamo’s collapse and the dispersal of its assets is a case study in a pattern that has recurred through biotech’s recent downturn.

Companies that raised heavily during favourable conditions built cost structures assuming continued access to capital. When the funding environment tightened, those with revenue survived and those dependent on the next round did not — regardless of whether their science was sound.

The consequence is that genuinely valuable assets reach the market at prices reflecting distress rather than worth. Buyers with balance sheets acquire late-stage programmes for a fraction of development cost, which is efficient in one sense and transfers value from the investors who funded the science to those holding capital when it ran out.

For patients the effect is mostly benign, provided a buyer emerges and continues development. The risk is programmes that find no buyer at all — assets in indications too small or too early to attract a bid, which simply stop, taking years of work and the hope of the patients waiting for them.

The remaining questions are the ones that apply to all gene therapy: whether enzyme production is durable over years as cells turn over, and whether long-term safety holds. For patients facing lifelong fortnightly infusions, a one-time alternative is worth considerable uncertainty. Business news, not investment advice.